<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129050</url>
  </required_header>
  <id_info>
    <org_study_id>SU-05042010-5842</org_study_id>
    <secondary_id>R21AT003465-01</secondary_id>
    <nct_id>NCT01129050</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 Fatty Acids on Markers of Inflammation</brief_title>
  <official_title>Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this study is to examine the effect of two sources of dietary omega-3&#xD;
      fatty acids, each given at two doses, on potential health benefits related to cardiovascular&#xD;
      disease prevention. The two sources of dietary omega-3 fatty acids will be fish oil, and&#xD;
      flaxseed oil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to examine the effect of two sources of dietary omega-3&#xD;
      fatty acids, each given at two doses, on potential health benefits related to cardiovascular&#xD;
      disease prevention. The two sources of dietary omega-3 fatty acids will be fish oil, and&#xD;
      flaxseed oil. Each will be given at a lower dose that could realistically be achieved from&#xD;
      food sources alone, and at a higher dose that could not realistically be achieved from food&#xD;
      alone and would require supplementation. The outcomes being studied are markers of&#xD;
      inflammation. The subjects being studied are those with elevated risk factors for diabetes&#xD;
      and heart disease that meet the criteria for the &quot;metabolic syndrome&quot;. These are the people&#xD;
      who are currently not diabetic, and who have not been diagnosed yet with heart disease, who&#xD;
      are at risk of developing these diseases and who would likely benefit the most from the&#xD;
      omega-3 therapy should it prove to be effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in inflammatory markers (MCP-1, IL-6, and sICAM-1) at 8 weeks.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change was calculated as the value at 8 weeks minus the value at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in red blood cells (RBC) Fatty Acids at 8 weeks.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change was calculated as the value at 8 weeks minus the value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in low-density lipoprotein (LDL) cholesterol at 8 weeks.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change was calculated as the value at 8 weeks minus the value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in high-density lipoprotein (HDL) cholesterol at 8 weeks.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change was calculated as the value at 8 weeks minus the value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in triglycerides at 8 weeks.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change was calculated as the value at 8 weeks minus the value at baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Low-dose Flaxseed Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.2 g ALA (alpha-linolenic acid) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Flaxseed Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.6 g ALA (alpha-linolenic acid) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 g or 6 g soybean oil per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Fish oil capsule</description>
    <arm_group_label>High-dose Fish Oil</arm_group_label>
    <arm_group_label>Low-dose Fish Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed Oil</intervention_name>
    <description>Flaxseed oil capsule</description>
    <arm_group_label>High-dose Flaxseed Oil</arm_group_label>
    <arm_group_label>Low-dose Flaxseed Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soybean oil capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Gender:&#xD;
&#xD;
          -  Both women and men&#xD;
&#xD;
          -  Age: &gt; or = 18 years&#xD;
&#xD;
          -  Ethnicity and race: All ethnic and racial backgrounds welcome&#xD;
&#xD;
          -  As defined in ATP III of the National Cholesterol Education program, the metabolic&#xD;
             syndrome will be diagnosed as presence of at least three of the following, which will&#xD;
             be measured at the screening clinic visit:&#xD;
&#xD;
        Central obesity as measured by waist circumference:&#xD;
&#xD;
          -  Men: Greater than 40 inches&#xD;
&#xD;
          -  Women: Greater than 35 inches&#xD;
&#xD;
               -  Fasting blood triglycerides greater than or equal to 150 mg/dL&#xD;
&#xD;
               -  Blood HDL cholesterol:&#xD;
&#xD;
          -  Men: Less than 40 mg/dL&#xD;
&#xD;
          -  Women: Less than 50 mg/dL&#xD;
&#xD;
               -  Blood pressure greater than or equal to 130/85 mmHg&#xD;
&#xD;
                    -  Fasting glucose greater than or equal to 100 mg/dL&#xD;
&#xD;
        Planning to be available for clinic visits and bottle pick-ups for the 8 weeks of study&#xD;
        participation&#xD;
&#xD;
        Ability and willingness to give written informed consent&#xD;
&#xD;
        No known active psychiatric illness.&#xD;
&#xD;
        Exclusion Criteria:Daily intake of dietary supplements containing omega-3 FAs within the&#xD;
        past month.&#xD;
&#xD;
          -  Fasting blood glucose &gt; 140 mg/dL&#xD;
&#xD;
          -  Significant liver enzyme abnormality&#xD;
&#xD;
          -  AST or ALT more than 2 times the upper limit of normal and/or&#xD;
&#xD;
          -  Bilirubin more than 50% the upper limit of normal&#xD;
&#xD;
          -  Renal disease as measured at baseline:&#xD;
&#xD;
          -  Serum creatinine &gt; 1.30 mg/dL, or&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 71 mL/min&#xD;
&#xD;
          -  Self reported personal history of:&#xD;
&#xD;
               -  Clotting disorders&#xD;
&#xD;
               -  Clinically significant atherosclerosis (e.g., CAD, PAD)&#xD;
&#xD;
               -  Malignant neoplasm&#xD;
&#xD;
               -  Ongoing infection&#xD;
&#xD;
               -  Inflammatory disease (e.g., rheumatoid arthritis)&#xD;
&#xD;
          -  Subjects currently receiving the following medications (self report):&#xD;
&#xD;
               -  Anti-Inflammatory drugs&#xD;
&#xD;
               -  Lipid lowering drugs including statins&#xD;
&#xD;
               -  Anti-hypertensive drugs&#xD;
&#xD;
               -  Anti-coagulant drugs&#xD;
&#xD;
          -  Body Mass Index (BMI) greater than or equal to 40.&#xD;
&#xD;
          -  Pregnant or Lactating&#xD;
&#xD;
          -  Inability to communicate effectively with study personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Gardner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD. Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr. 2011 Dec;141(12):2166-71. doi: 10.3945/jn.111.142240. Epub 2011 Oct 26.</citation>
    <PMID>22031659</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Christopher Gardner</investigator_full_name>
    <investigator_title>Professor of Medicine (Research)</investigator_title>
  </responsible_party>
  <keyword>Fish oil</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

